Nozawa Hiroaki, Ito Sono, Sasaki Kazuhito, Murono Koji, Emoto Shigenobu, Yokoyama Yuichiro, Yamauchi Shinichi, Kinugasa Yusuke, Ajioka Yoichi, Ishihara Soichiro
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Study Group for Paraaortic Lymph Node Metastases, The Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan.
Ann Surg Oncol. 2025 Apr;32(4):2282-2291. doi: 10.1245/s10434-024-16537-6. Epub 2024 Nov 18.
BACKGROUND: Surgical removal of metastasized paraaortic lymph nodes (PALNs) can prolong the survival of certain patients with colorectal cancer (CRC). However, the role of postoperative chemotherapy in such patients remains unknown. PATIENTS AND METHODS: This multicenter retrospective study examined 97 patients with PALN metastasis from CRC who underwent surgical resection at 36 centers in Japan between 2010 and 2015. On the basis of adjuvant chemotherapy (AC) after the lymphadenectomy, patients were classified into non-AC and AC groups (27 and 70 patients, respectively). After the exclusion of patients receiving irinotecan, the latter group was further categorized into 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) subgroups (14 and 52 patients, respectively) according to the use of L-OHP. Background characteristics and postoperative survival were compared among the groups. RESULTS: Marked differences were not seen in background characteristics, except for neoadjuvant treatment, between the non-AC and AC groups. The AC group exhibited better recurrence-free survival (RFS; p = 0.009) and overall survival (OS; p = 0.040 by the Wilcoxon test) than the non-AC group. However, RFS and OS of the 5-FU group did not differ from those of the L-OHP group (p = 0.73 and p = 0.92 by the Wilcoxon test, respectively). CONCLUSIONS: AC may be associated with improved prognosis of patients after the removal of PALN metastasis from CRC, but L-OHP did not offer additional survival benefits. Prospective studies comparing non-AC with 5-FU- and L-OHP-based AC are needed to confirm these findings.
背景:手术切除转移性主动脉旁淋巴结(PALN)可延长某些结直肠癌(CRC)患者的生存期。然而,术后化疗在此类患者中的作用尚不清楚。 患者与方法:这项多中心回顾性研究对2010年至2015年间在日本36个中心接受手术切除的97例发生PALN转移的CRC患者进行了检查。根据淋巴结清扫术后的辅助化疗(AC)情况,将患者分为非AC组和AC组(分别为27例和70例患者)。在排除接受伊立替康治疗的患者后,根据奥沙利铂(L-OHP)的使用情况,将后一组进一步分为5-氟尿嘧啶(5-FU)亚组和奥沙利铂(L-OHP)亚组(分别为14例和52例患者)。比较各组的背景特征和术后生存率。 结果:非AC组和AC组之间,除新辅助治疗外,背景特征未见明显差异。AC组的无复发生存期(RFS;p = 0.009)和总生存期(OS;Wilcoxon检验p = 0.040)均优于非AC组。然而,5-FU组的RFS和OS与L-OHP组无差异(Wilcoxon检验分别为p = 0.73和p = 0.92)。 结论:AC可能与CRC患者PALN转移切除术后预后改善有关,但L-OHP并未提供额外的生存益处。需要进行前瞻性研究,比较非AC与基于5-FU和L-OHP的AC,以证实这些发现。
World J Surg Oncol. 2011-12-30
J Cancer Res Clin Oncol. 2014-1-12
J Gastrointest Surg. 2013-9-4